Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension.
Harbaum, L; Rhodes, CJ; Wharton, J; Lawrie, A; Karnes, JH; Desai, AA; Nichols, WC; Humbert, M; Montani, D; Girerd, B; et al.
American Journal of Respiratory and Critical Care Medicine.
2022;
205:1449-1460.
COL18A1 genotypic associations with endostatin levels and clinical features in pulmonary arterial hypertension: a quantitative trait association study.
Simpson, CE; Griffiths, M; Yang, J; Nies, MK; Vaidya, D; Brandal, S; Martin, LJ; Pauciulo, MW; Lutz, KA; Coleman, AW; et al.
ERJ Open Research.
2022;
8.
Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension.
Toshner, M; Church, C; Harbaum, L; Rhodes, C; Villar Moreschi, SS; Liley, J; Jones, R; Arora, A; Batai, K; Desai, AA; et al.
European Respiratory Journal.
2022;
59.
Biomarkers of Pulmonary Hypertension Are Altered in Children with Down Syndrome and Pulmonary Hypertension.
Griffiths, M; Yang, J; Vaidya, D; Nies, M; Brandal, S; Ivy, DD; Hickey, F; Wolter-Warmerdam, K; Austin, ED; Mullen, M; et al.
Journal of Pediatrics.
2022;
241:68-76.e3.
Hepatoma-derived growth factor is associated with pulmonary vascular remodeling and PAH disease severity and survival.
Yang, J; Ambade, AS; Nies, M; Griffiths, M; Damico, R; Vaidya, D; Brandal, S; Pauciulo, MW; Lutz, KA; Coleman, AW; et al.
Pulmonary Circulation.
2022;
12.
Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH.
Zhu, N; Swietlik, EM; Welch, CL; Pauciulo, MW; Hagen, JJ; Zhou, X; Guo, Y; Karten, J; Pandya, D; Tilly, T; et al.
Genome Medicine.
2021;
13.
Validation of low-coverage whole-genome sequencing for mitochondrial DNA variants suggests mitochondrial DNA as a genetic cause of preterm birth.
Yang, Z; Slone, J; Wang, X; Zhan, J; Huang, Y; Namjou, B; Kaufman, KM; Pauciulo, M; Harley, JB; Muglia, LJ; et al.
Human Mutation.
2021;
42:1602-1614.
Angiostatic Peptide, Endostatin, Predicts Severity in Pediatric Congenital Heart Disease-Associated Pulmonary Hypertension.
Daly, CM; Griffiths, M; Simpson, CE; Yang, J; Damico, RL; Vaidya, RD; Williams, M; Brandal, S; Jone, PN; Polsen, C; et al.
Journal of the American Heart Association.
2021;
10.
The angiostatic peptide endostatin enhances mortality risk prediction in pulmonary arterial hypertension.
Simpson, CE; Griffiths, M; Yang, J; Nies, MK; Vaidya, RD; Brandal, S; Martin, LJ; Pauciulo, MW; Lutz, KA; Coleman, AW; et al.
ERJ Open Research.
2021;
7.
Subthalamic Peak Beta Ratio Is Asymmetric in Glucocerebrosidase Mutation Carriers With Parkinson's Disease: A Pilot Study.
David, FJ; Munoz, MJ; Shils, JL; Pauciulo, MW; Hale, PT; Nichols, WC; Afshari, M; Sani, S; Verhagen Metman, L; Corcos, DM; et al.
Frontiers in Neurology.
2021;
12.